Triple negative breast cancer (TNBC) represents approximately 10-15% of all breast cancer diagnoses but accounts for a disproportionately high percentage of breast cancer deaths. What sets this ...

Datopotamab deruxtecan indicated for patients ineligible for immunotherapy ...

The FDA has approved datopotamab deruxtecan (Dato-DXd, Datroway, Daiichi Sankyo) for the treatment of patients with ...

The Food and Drug Administration (FDA) on May 22, 2026, approved Datroway (datopotamab deruxtecan-dlnk) for adult patients ...

SAN ANTONIO -- Postmastectomy chest-wall irradiation (CWI) for intermediate-risk breast cancer had no impact on long-term survival, results of a large British study showed. After a median follow-up of ...

Strides in cancer research are happening in Dallas. Most recently, breast cancer doctors say they may have found a new way to fight one of the most devastating subtypes of cancer. UT Southwestern ...

A small clinical trial shows promising results for patients with triple-negative breast cancer who received an investigational vaccine designed to prevent recurrence of tumors. Conducted at Washington ...

Dr. Elisa Port draws on patient stories like Martin's and Evert's and 25 years of experience for a new book on breast care ...

Cleveland Clinic researchers are presenting updated findings from their novel study of a vaccine aimed at preventing triple-negative breast cancer, the most aggressive and lethal form of the disease.

At the age of 29, Amy Lynn Safaty had both of her breasts surgically removed. "When I woke up completely flat before I had reconstruction, I thought, ‘Oh my God, what did I do?’" What she did was ...